Screener
Vor Biopharma VOR Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220689
| (in thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 28 | 825 |
| Non-cash lease expense | 109 | 1,310 |
| Stock-based compensation | 8,870 | 1,933 |
| Change in fair value of warrant liabilities | 188,360 | — |
| Interest amortization on marketable securities | (488) | (11) |
| Loss on sale of property and equipment | — | 1 |
| Changes in operating assets and liabilities: |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Vor Biopharma's stock-based comp?
- Vor Biopharma (VOR) reported stock-based comp of $8.87M in Q1 2026.
- How has Vor Biopharma's stock-based comp changed year-over-year?
- Vor Biopharma's stock-based comp increased by 358.9% year-over-year, from $1.93M to $8.87M.
- What is the long-term trend for Vor Biopharma's stock-based comp?
- Over 4 years (2021 to 2025), Vor Biopharma's stock-based comp has grown at a 44.7% compound annual growth rate (CAGR), from $4.32M to $18.91M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Vor Biopharma's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude